Diligence memo · auto-generated · as of July 2, 2026
NeuroTherapeutics Pharma, Inc.
NeuroTherapeutics Pharma, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
NeuroTherapeutics Pharma, Inc. operates in Biotechnology, based in CHICAGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
NeuroTherapeutics Pharma, Inc. has raised $34M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $19M on 2010-05-20.
Most recent recorded round closed around 2011-12-15.
Valuation (modeled)modeled
Provath models NeuroTherapeutics Pharma, Inc. at approximately $476M (range $24M–$1.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.73× the median modeled value of Series B Biotechnology companies in 2010–2012 (48 peers) — value vs value, same stage and era. Within the normal band (73% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 18 months.
Last raise 14.5 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 76% of Biotechnology peers (4293 compared).
Modeled value ranks above 83% of those peers.
Closest niche peers: Redpoint Bio CORP, Cardiaq Valve Technologies Inc, Visterra, Inc., Celltex Therapeutics Corp, Crown Bioscience, Inc.
Peoplefiled
20 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.